ABSTRACT
INTRODUCTION
Red-cell alloimmunization affects up to 0.6% of all live births, and can be successfully treated with intrauterine fetal blood transfusion (IUT). Doppler measurement of fetal middle cerebral artery (MCA) peak systolic velocity (PSV) is a non-invasive test that can identify fetuses at risk of anemia and in need of IUT 1 . As originally described by Mari et al. 2 , a MCA-PSV above 1.5 multiples of the median (MoM) indicates moderate or severe fetal anemia, with a sensitivity of 100% and false-positive rate (FPR) of 12% 2, 3 . Despite its limitations, MCA-PSV is widely used, compares favorably with amniotic fluid bilirubin concentrations for identifying the fetus at risk of anemia and has largely replaced serial amniocentesis in managing red-cell alloimmunization 4, 5 . Traditionally, the timing of subsequent IUTs involves estimating the rate of red-cell destruction, by a reduction in either fetal hematocrit (Hct) or fetal hemoglobin [6] [7] [8] [9] [10] . Correction of fetal anemia following IUT normalizes the fetal MCA-PSV, extending its potential for timing subsequent procedures [10] [11] [12] [13] [14] [15] . However, as highlighted by Moise 16 , this potential is not supported by available data. Detti et al. 13 used a MCA-PSV > 1.69 MoM to identify correctly all fetuses with severe anemia following a single IUT, with a FPR of 6%. However, following two or more IUTs, MCA-PSV values above 1.5 MoM have variably identified severe fetal anemia with a sensitivity of between 84% and 100%, with FPRs in the order of 50% 10, 14, 15 . Indeed, a recent study has indicated that, particularly after second IUTs, several formulae to estimate red-cell destruction are more accurate than MCA-PSV 17 . We conducted a pragmatic trial to evaluate whether measurement of MCA-PSV is non-inferior to estimation of decrease in fetal Hct or hemoglobin level in determining timing of subsequent IUTs, without compromising hemoglobin levels at birth, in fetuses that had undergone one IUT for anemia secondary to red-cell alloimmunization.
METHODS
This was a multicenter, randomized controlled trial including women with a singleton pregnancy complicated by fetal anemia secondary to red-cell alloimmunization, due to any red-cell antibody (alone or in combination), as indicated by the need to undergo a single IUT. Pregnant women with anemic fetuses secondary to any other cause, or with known chromosomal anomaly, were not eligible for inclusion. Eligible women were identified after a decision to proceed with the first IUT, and provided written informed consent to participate in the trial, which was registered on the Australian and New Zealand Clinical Trials Register (ACTRN12608000643370).
An online randomization service with a computergenerated schedule using balanced variable blocks was used, and stratification for the presence or absence of hydrops at first IUT, type of antibody (Kell vs other) and place of birth was carried out. Women were randomized to the timing of subsequent transfusion by measurement of MCA-PSV (MCA-PSV Group), with a serial upward trend and MCA-PSV values >1.5 MoM indicative of the need for another IUT, or to timing of subsequent transfusion by estimation of a decrease in fetal Hct (fetal Hct Group), in which a subsequent IUT was timed according to an estimated decrease in fetal Hct of 1% per day or fetal hemoglobin of 0.3 g/dL per day.
Treatment schedules
Women in the MCA-PSV Group underwent serial ultrasound examination performed in a standard fashion and at a frequency determined by individual clinicians experienced in the management of fetal alloimmunization 3 . Briefly, measurements were made in the absence of fetal breathing movements, with the woman in a semirecumbent position. An axial section was obtained through the fetal brain, caudal to the level required for measurement of the biparietal diameter, with identification of the MCA using color or power Doppler settings, and an angle of insonation of 0-10
• ; the angle correction did not exceed 3
• . The sample volume was placed near the internal carotid artery, and a measurement of the peak Doppler waveform taken after obtaining five representative waveforms. Consistent with practices within each participating fetal medicine unit, the MCA-PSV value was recorded in a standardized fashion, and an upward serial trend in values consistently >1.5 MoM was considered indicative of the need for IUT. De novo identification of ascites and/or hydrops was additionally considered indicative of the need for IUT, regardless of the MCA-PSV value.
In women randomized to the fetal Hct Group, the timing of subsequent IUTs was planned using standard criteria to predict the rate of red-cell destruction and development of anemia, based on gestational age, hemoglobin level prior to IUT and hemoglobin level at completion of IUT [6] [7] [8] . Fetal Hct level was estimated to fall by 1% per day and fetal hemoglobin was estimated to fall by 0.3 g/dL per day. IUT was undertaken according to standard practice within each center, to maintain fetal hemoglobin level between 7 and 10 g/dL 9, 10 .
In both treatment groups, women beyond 24 weeks' gestation were administered antenatal corticosteroids for fetal lung maturation 1, 18 . Transfused blood was fresh, matched to the woman's blood group, cytomegalovirus negative and irradiated, with Hct between 75% and 80%. IUTs were performed under ultrasound guidance by appropriately trained staff 1 . The site of transfusion (umbilical cord, intrahepatic vein or intraperitoneal) and use of fetal paralysis were at the discretion of individual clinicians, in accordance with individual and institutional practices 1, 19, 20 . The transfused blood volume was based on gestational age, estimated fetal weight and pretransfusion hemoglobin level, with a post-transfusion specimen obtained when possible 1, 21 . The target post-transfusion hemoglobin level was 4 g/dL below the mean for gestational age 6, 7 . Following the procedure, monitoring of fetal heart rate and uterine activity was performed.
Decisions relating to the timing of the last IUT and of optimal timing of birth for women with red-cell alloimmunization are uncertain, with recommendations for birth ranging from after 32 to 36 or 38 weeks' gestation 1, 22, 23 . In the context of this pragmatic trial, these decisions were made following discussion between the woman and her caregivers. At birth, a cord blood sample was taken to estimate hemoglobin and/or Hct. Clinical outcomes were abstracted from case notes after birth. Patients and caregivers were not blinded to treatment allocation, although, when possible, staff assessing outcomes were.
Outcomes
The primary outcome was the level of infant cord blood hemoglobin at birth. Secondary outcomes included: (1) adverse infant outcome related to alloimmunization, including one or more of stillbirth (intrauterine fetal death after entry into the trial and prior to birth), neonatal death (death of a liveborn infant before 28 days of age), severe fetal anemia at the time of the second or any subsequent IUT (defined as pretransfusion hemoglobin level ≥ 5 SD below the mean for gestational age, with the mean hemoglobin for gestational age defined according to the formula 6 : mean hemoglobin = 11 + ((GA -17) × 0.19) where GA is gestational age in weeks, severe anemia at birth (hemoglobin ≥5 SD below the mean for gestational age) or neonatal exchange transfusion; (2) procedure-related complications necessitating emergency birth, including one or more of the following within 1 week of the procedure: preterm prelabor rupture of membranes (PPROM), preterm labor, chorioamnionitis, placental abruption or antepartum hemorrhage; (3) infant complications related to alloimmunization, including preterm birth before 34 weeks' gestation, jaundice requiring treatment, admission to the neonatal intensive care unit or neonatal top-up transfusion; (4) maternal complications including antepartum hemorrhage or abruption, PPROM, threatened preterm labor or chorioamnionitis; and (5) number of IUTs after randomization.
Sample size
The sample size and primary outcome were modified prior to finalizing the trial data, and before any of the planned analyses were performed, to account for slowerthan-anticipated recruitment and to reflect the available funding. Assuming an infant hemoglobin SD of 1 g/dL, a sample of 35 participants per group (70 in total) would provide 80% power (two-sided alpha = 0.05) to detect non-inferiority, with a non-inferiority margin of 0.6 g/dL.
The original sample size was 536 women, to detect a 30% reduction in a primary composite adverse outcome (stillbirth, neonatal death, severe fetal anemia, severe anemia at birth, neonatal exchange transfusion) at the 5% significance level and 90% power.
Statistical analysis
An intention-to-treat approach was used in analyses. Baseline characteristics of the women were used as an indication of comparable treatment groups, and included maternal age, race, height, weight, smoking history and obstetric history (including previous alloimmunized pregnancy and previous preterm birth or perinatal loss related to alloimmunization). No imputation was performed for missing data.
The effect of treatment was estimated using linear regression models for continuous outcomes, log binomial regression for binary outcomes and log Poisson regression for count outcomes. Estimates are difference in means (MCA-PSV -fall in Hct), relative risk (MCA-PSV/fall in Hct) and rate ratio (MCA-PSV/fall in Hct), along with 95% CIs. For the number of transfusions an offset was included for the number of days between randomization and delivery.
Both unadjusted and adjusted analyses were performed, adjusted analyses including the stratification variables 'presence of hydrops' and 'antibody type' (Kell vs other) as covariates. A small number of events were observed for many outcomes, which led to convergence issues with the models. If the number of events was too low to allow for adjustment, only unadjusted analyses were performed; if the number of events was too low for any modeling, Fisher's exact test was performed.
RESULTS
Between October 2009 and October 2013, 73 women were randomized from 13 centers in Australia, New Zealand, Canada, the UK, Ireland, Belgium and Argentina. One woman was randomized in two subsequent pregnancies but only the first pregnancy was included, and a further two women were randomized in error. Thus, a total of 71 women were analyzed, 36 in the MCA-PSV Group and 35 in the fetal Hct Group (Figure 1) . Baseline characteristics were similar between the two groups ( Table 1 ). The mean age of the women was 33.6 ± 4.7 years, and gestational age at randomization was 30.3 weeks (interquartile range, 27.7-32.0 weeks).
Women who consented to participate and were randomized to study groups (n = 75)
Included in analysis: fetal Hct Group (n = 35) Figure 1 Flowchart of participants in a randomized controlled trial of fetal middle cerebral artery peak systolic velocity (MCA-PSV) to time intrauterine transfusion in red-cell alloimmunization. Hct, hematocrit. Data given as mean ± SD, median (IQR) or n (%). *Percentage given as proportion of women who had any previous pregnancy that progressed beyond 20 weeks' gestation.
Overall 60.6% of participants were Caucasian and 25.4% were Hispanic. Most women were non-smokers (85.9%), had no evidence of fetal hydrops at first IUT (85.9%) and had alloimmunization antibodies other than Kell (90.1%).
One stillbirth occurred at 31 weeks in a fetus with hydrops randomized to the fetal Hct Group, between randomization and the scheduled second IUT. In addition, neonatal death occurred in five cases, three in the MCA-PSV Group and two in the fetal Hct Group. Two infants in the MCA-PSV Group had hydrops and died following preterm birth within the week following the first IUT (at 29 and 30 weeks, respectively) owing to complications of prematurity. The third infant was born at 33 weeks and died secondary to liver failure following multiple exchange and top-up transfusions in the postnatal period, and severe respiratory distress syndrome. One infant in the fetal Hct Group required five IUTs, but died following preterm birth, and within 1 week of the last IUT, at 28 weeks' gestation. The infant's hemoglobin count at birth was 9.7 g/dL, and complications of prematurity were compounded by an undiagnosed complex congenital cardiac lesion. The second infant was born at 33 weeks' gestation within a week of the second IUT. Complications of prematurity were compounded by sepsis and multiorgan failure.
No statistically significant difference was observed between the two treatment groups with regard to mean hemoglobin level (MCA-PSV Group, 10.36 ± 3.82 g/dL vs fetal Hct Group, 12.03 ± 3.14 g/dL; adjusted mean difference (aMD) -1.56 g/dL (95% CI, -3.24 to 0.13 g/dL); P = 0.070), or mean number of IUTs after randomization (MCA-PSV Group, 1.75 ± 1.79 vs fetal Hct Group, 1.80 ± 1.32; adjusted relative risk (aRR) 0.88 (95% CI, 0.61-1.26); P = 0.474) ( Table 2 ).
In addition, no statistically significant difference was observed with respect to procedure-related or maternal complications (Table 3 ). There was no evidence to suggest that outcomes varied according to the presence of hydrops at first IUT or the responsible antibody (data not shown). Data given as mean ± SD or n (%). Denominators for each outcome differ slightly as there was no imputation for missing data. Effects are differences in mean (MCA-PSV -fall in Hct). *Adjustment, unless otherwise indicated, for presence of hydrops at randomization and for antibody type (Kell vs other). †Analyzed using log Poisson regression; model included offset for number of days between randomization and delivery. ‡Adjustment for antibody type only (no events in one hydrops category). §Adverse fetal or neonatal outcome defined as one or more of: severe fetal anemia after randomization, stillbirth, severe anemia at birth, neonatal death and need for neonatal exchange transfusion. ¶Too few events to allow for modeling; P from Fisher's exact test. BW, birth weight; GA, gestational age; Hb, hemoglobin; NA, not available; NICU, neonatal intensive care unit.
DISCUSSION

Principal findings
Doppler measurement of MCA-PSV for estimating the timing of subsequent IUTs is not inferior to estimation of timing based on the expected decrease in fetal Hct. However, infants born when Doppler MCA-PSV was used to time subsequent IUTs had a non-statistically significant trend towards a lower mean hemoglobin level at birth (10.36 g/dL vs 12.03 g/dL) and more frequent need for neonatal exchange transfusion (40.0% vs 26.5%) when compared with those born after decline in fetal Hct was used to estimate timing of subsequent IUTs. No significant differences were identified with regard to other alloimmunization or procedure-related complications.
Comparison with other studies
The procedure-related complication risk in our trial was 2.8%, with an overall survival rate of 93%, both of which are consistent with the values of 3.1% and > 90%, respectively, reported in the literature 20 .
However, Zwiers et al. 24 recently reported their extensive 27-year experience involving almost 1700 transfusion procedures from a single tertiary referral center. In this cohort, survival improved from approximately 89% to 97%, and procedure-related complications declined from 3.4% to 1.2% for the time periods 1998-2001 and 2001-2014, respectively. These high survival rates and low complication rates are probably the 'best case scenario', reflective of both clinician experience and volume of procedures undertaken, as compared with our more pragmatic study design 24 .
Approximately 30% of infants in our trial had severe anemia at birth, with 85% receiving phototherapy for treatment of jaundice. One third of infants received at least one exchange transfusion, and 60% at least one top-up transfusion. Infants in the MCA-PSV Group tended to have lower levels of hemoglobin at birth and were more likely to receive an exchange transfusion, when compared with those in the fetal Hct Group. While these differences were not statistically significant, probably reflecting the sample size, they would be clinically significant in neonatal care. Neonatal outcomes reported in our trial are not directly comparable with those of other study populations reported in the literature. All the infants in our population required at least one IUT, in contrast to other reports, in which outcome comparisons largely reflected the presence or absence of an antenatal transfusion. van Kamp et al. 25 reported neonatal outcomes for 191 infants born after any IUT. While the mean hemoglobin level reported at birth was consistent with our findings, it is difficult to compare other outcomes, as they reported the median number of exchange and top-up transfusions, rather than the number of infants requiring this treatment 25 . A study from the UK followed 28 women with alloimmunized pregnancies by means of MCA-PSV 26 . Reported neonatal complication rates were lower than those identified in our trial, with 36% of infants requiring phototherapy for jaundice, 25% an exchange transfusion and 14% a top-up transfusion 26 . De Boer et al. 27 reported outcomes for 89 infants with Rhesus hemolytic disease, in which 52 infants required an IUT. In this series, while 71% of infants who required an IUT also received an exchange transfusion, they required less phototherapy but more top-up transfusions than did infants who were not treated in the antenatal period, although again, the comparator was infants who did not require an IUT 27 .
Strengths and limitations of the study
To our knowledge, this is the first randomized controlled trial evaluating the efficacy of Doppler MCA-PSV for determining the timing of second and subsequent IUTs in fetuses with red-cell alloimmunization. We utilized robust methodology and prespecified relevant maternal and infant outcomes, and followed a prespecified analysis plan.
While the primary outcome and sample size were modified from the original trial registration to account for slower-than-anticipated recruitment and available funding, this was done prior to finalizing data collection and before undertaking any prespecified analyses. The trial was adequately powered to identify relatively small differences in hemoglobin concentration at birth between the two treatment methodologies, but not differences in less common clinical outcomes.
We encountered several problems when conducting this trial, reflecting the need to involve multiple centers internationally to study a relatively uncommon condition. Considerable delay was experienced in commencing recruitment, with mean time to obtain ethical approval in centers in which recruitment occurred being 305 days (range, 92-608 days). This delay was greater in centers in which the ethical approval process was commenced, but recruitment did not occur (mean 518 days (range, 153-1095 days)). Many clinical collaborators indicated that time pressures and a lack of research support hampered their participation, although provision of dedicated research support at each site was not possible, with only modest financial reimbursement provided per participant recruited. Unfortunately, there were considerable time delays between investigators providing agreement to participate and securing funding. Over this time, there had been a shift in clinical practice such that many large referral centers internationally had started to use routinely MCA-PSV to time second and subsequent IUTs, and were therefore no longer willing to participate.
Conclusions
Our findings indicate that both Doppler MCA-PSV measurement and estimating the decrease in fetal Hct or hemoglobin level can be used to time second and subsequent IUTs. However, the trend towards lower infant hemoglobin levels, increased need for exchange transfusion and the increased frequency of visits for ultrasound surveillance associated with MCA-PSV assessment have resource implications for the woman and healthcare facilities, and are valid considerations in determining the most appropriate method to time IUTs.
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